

US EPA ARCHIVE DOCUMENT

Environmental Protection Agency

PESTICIDE FACT SHEET

METHOPRENE

Methoprene is an insect growth regulator (IGR) with activity against a variety of insect species including horn flies, mosquitoes, beetles, tobacco moths, sciarid flies, fleas (eggs and larvae), fire ants, pharaoh ants, midge flies and Indian meal moths. Controlling some of these insects, methoprene is used in the production of a number of foods including meat, milk, mushrooms, peanuts, rice and cereals. It also has several uses on domestic animals (pets) for controlling fleas. Methoprene products are sold under a number of trade names including Altosid®, Precor®, Kabat®, Phorid®, Dianex®, Apex®, Fletrol™, Ovitrol®, Extinguish® and Diacon®. Methoprene is considered a biochemical pesticide because rather than controlling target pests through direct toxicity, Methoprene interferes with an insect's life cycle and prevents it from reaching maturity or reproducing.

Regulatory History

Methoprene was first registered by EPA as a conventional, chemical pesticide in 1975. EPA issued a Registration Standard for Methoprene in February 1982. Subsequently, the Agency reclassified Methoprene as a biochemical pesticide. The Agency issued the Reregistration Eligibility Document (RED) in 1991 and reregistration of the active ingredient and all end-use products was completed in 1997. Tolerances (40 CFR 180.359) and exemption from tolerances (40 CFR 180.1033 and 185.4150) have been established for Methoprene in or on a number of food commodities. Methoprene is also recognized by FDA as a feed additive for use in cattle feeds to control horn flies (40 CFR 186.4150; formerly 21CFR 561.282).

Health Effects

An extensive safety data base has been generated for Methoprene since it was first registered in 1975. Toxicological data on file with the Agency includes an acute toxicity battery, irritation/sensitization studies, subchronic feeding studies, developmental and reproductive toxicity studies, mutagenicity studies, chronic feeding studies and lifetime carcinogenicity studies. In addition, special studies dealing with the metabolism and fate of Methoprene in several mammalian species and those dealing with the potential for endocrine effects have also been completed. Studies relating to the effect of Methoprene on the immune system were waived by EPA since there was no indication of the immune system being the potential target organ/system in any of the acute, subchronic, chronic, teratology, reproduction or special toxicity studies. Today, some of the submitted data would not even be required under the current guidelines for biochemical pesticides.

In addition to the studies mentioned above, the following data gaps identified in the March 1991 RED document have been completed:

1. Estuarine Invertebrate Life Cycle Study – MRID #44022101
2. Octanol/Water Partition Coefficient Study – MRID #42290001

The results from various toxicology studies for Methoprene are summarized below:

- The acute oral LD₅₀ for racemic and (S)-Methoprene in rats is >10,000¹ and >5000² mg/kg, respectively. These doses were the highest doses tested (HDT) for both compounds. In dogs, the acute oral LD₅₀ value for racemic Methoprene is between 5000 to 10,000³ mg/kg. The acute dermal LD₅₀ for both racemic⁴ and (S)-Methoprene⁵ in rabbits is >2000 mg/kg. The acute (4-hr) inhalation LC₅₀ for racemic Methoprene in the rat⁶ and guinea pig⁷ is >210 mg/L. Primary eye and skin irritation studies have been conducted in rabbits for both racemic and (S)-Methoprene. Results from these studies indicate that both racemic^{8,9} and (S)-Methoprene^{10,11} are not likely to cause irritation to the skin or eyes of humans when exposed topically. Also, based on data generated for racemic Methoprene in guinea pigs¹², no potential for skin sensitization is expected for (S)-Methoprene. These data indicate an extremely low potential for acute toxicity to humans from overexposure to either racemic or (S)-Methoprene via the oral, dermal, ocular or inhalation routes of exposure. S-Methoprene is classified in toxicity categories III and IV. In order to evaluate health effects from short-term exposure, 90-day feeding studies¹³ have been conducted with racemic Methoprene in rats given doses of 0, 250, 500, 1000 or 5000 ppm in diet and in dogs given doses of 0, 250, 500 or 5000 ppm in diet. The No-Observable-Effect Level (NOEL) for systemic effects was 500 ppm for both rats and dogs. Increased liver weights in rats and dogs and renal tubular degeneration effects in some rats were observed at higher dose levels but the significance of these effects are considered negligible since they were not observed in chronic feeding studies. A 30-day dermal toxicity study has been conducted in Japanese rabbits with undiluted Methoprene at doses of 0, 100, 300, 900 or 2700 mg/kg/day applied topically to the back of the rabbits¹⁴. The 300 mg/kg dose was concluded to be the NOEL for systemic effects and 100 mg/kg was considered to be the NOEL for local effects. The NOEL for racemic Methoprene was 20 mg/L (HDT) in a 21-day inhalation toxicity study in rats¹⁵. These data indicate that oral, dermal or inhalation exposure to Methoprene for an extended duration is not likely to cause adverse health effects in humans.
- Chronic feeding studies have been conducted in rats¹⁶ and mice¹⁷. Rats exposed to Methoprene technical at 0, 250, 1000, or 5000 ppm in the diet daily for two years did not exhibit any adverse health effects even at the highest dose as compared to control animals¹⁶. No increase in tumor incidence was observed. The NOEL for systemic effects was 5000 ppm, the highest dose tested in the study. No potential for increase in tumors was observed in another chronic study using CD-1 mice fed diets containing 0, 250, 1000 or 2500 ppm of Methoprene daily for 18 months¹⁷. No significant health effects were observed in treated groups. The NOEL for systemic effects in mice was concluded to be 250 mg/kg/day due to the presence of brown pigmentation of the liver in some animals at higher doses. It can therefore be concluded that Methoprene is not an oncogenic compound based on the chronic toxicity studies summarized above.

- Complete data are available for evaluating the developmental and reproductive effects of Methoprene in animals. Methoprene is not a developmental toxicant as evaluated in rabbits (NOEL 2000 mg/kg, the highest dose tested)¹⁸ and mice (NOEL 600 mg/kg/day, the highest dose tested)¹⁹. The three-generation reproduction study conducted in rats also revealed a NOEL of 2500 ppm (HDT) for reproductive effects²⁰. With such high NOELs for Methoprene in these studies at the highest doses tested, no developmental toxicity can be expected in humans from exposure to the residues of Methoprene either during pregnancy or during early childhood.
- Methoprene is not a mutagenic compound based on negative results obtained in the Ames test and several other mutagenicity assays^{21, 22, 23, 24}.
- Special studies relating to mammalian metabolism²⁵ indicate that Methoprene is metabolized rapidly and extensively into endogenous products such as acetate molecules and these are incorporated into the biosynthesis of naturally occurring constituents of the body such as cholesterol and bile acids.
- Screening studies relating to endocrine effects indicate that Methoprene has no potential for an estrogenic, androgenic, anabolic or a glucocorticoid effect²⁶. In addition, any potential for these effects would have been revealed in the developmental studies and/or the three-generation reproduction study where animals were exposed to high levels of Methoprene technical.

Routes of Human Exposure

Through the Diet

Dietary exposure to Methoprene is minimal and would only be expected to occur from treatment of mushrooms, stored grains, peanuts and cereals or low-level residues in cattle meat, fat or milk from feed-through applications. Methoprene has been in use for over two decades. The stored grain uses are at a maximum 5 ppm rate. No health hazards have been reported that could be related to the ingestion of Methoprene residues. Residues of Methoprene are at negligible levels particularly with respect to the NOEL levels in the developmental and reproductive toxicity studies. Due to the high toxicological endpoints and low levels of residues, risk from consumption of treated commodities is considered negligible for the general population and infants and children.

Through Drinking Water

Exposure to Methoprene residues is not expected from drinking water. In aqueous solutions, Methoprene degrades rapidly under sunlight into at least 50 minor photolysis products^{27, 28}. Methoprene is rapidly metabolized in soil both under aerobic and anaerobic conditions (half-life 10-14 days) with CO₂ as the major product²⁹. Degradation in surface water is due to both microbial metabolism and photolysis^{27, 30}. By the time surface water reaches drinking water treatment plants, residues of Methoprene are unlikely to be present and in the unlikely event that residues are present, these would be mitigated by water treatment procedures. In view of these points, drinking water is not considered an additive factor in exposure of the human population to Methoprene.

During Application

Non-Dietary Exposure is considered minimal with respect to mixers, loaders and applicators since exposure via dermal and inhalation routes are negligible and Methoprene is classified in toxicity category III and IV for dermal and inhalation toxicity, respectively. Furthermore, no evidence exists for neurotoxic, oncogenic, reproductive or developmental adverse effects that can be attributed to Methoprene. EPA considers Methoprene to pose no risks to people who are occupationally exposed to this biopesticide.

Domestic Animals

The Agency is reviewing submitted data regarding the safety of Methoprene use on domestic animals. It is used on pets (dogs and cats) and in pet areas (bedding). Incidents of toxicity to cats from the use of products containing Methoprene have been reported to the Agency. EPA is investigating these incidents and evaluating domestic animal safety data for Methoprene to determine if the cause of the reported incidents is due to Methoprene or another ingredient in the products. Once the cause of the adverse effect incidents is known the Agency will take appropriate regulatory action.

Environmental Hazards

Environmental Fate

All the environmental fate data requirements for Methoprene have been satisfied. The available information indicates that Methoprene will not result in unreasonable adverse effects on the environment since Methoprene degrades rapidly in sunlight²⁷, both in water²⁸ and on inert surfaces. Methoprene is also metabolized rapidly in soil and does not leach²⁹. Thus, Methoprene is not expected to persist in soil or contaminate ground water.

Ecological effects

Methoprene has been shown to be practically non-toxic to terrestrial species including mallard ducks³¹ and quail³² and Methoprene had no effect on mallard³³ or quail³⁴ reproduction.

Ecological effects studies on aquatic species either on file with the Agency or submitted by the registrant between 1993 and 1996, indicate minimal acute and chronic risk to freshwater fish^{35,36,37}, freshwater invertebrates^{38,39} and estuarine species^{40,41,42,43} from exposure to Methoprene mosquito products.

Extensive research has addressed the effects of Methoprene on non-target aquatic and terrestrial organisms. Acute, short-term and subchronic effects studies on non-target immature and adult arthropods [Crustacea, Insecta and Mollusca, including shrimp, damselfly, beetle, tadpole] demonstrate 24- and 48- hour LC₅₀ values >900 ppb^{44,45}. Confirming these studies, other researchers have demonstrated that sensitive life stages of nontarget organisms, *i.e.*, nymph and larvae, and

nontarget aquatic organisms that are highly related to mosquitoes, *i.e.*, dragonfly, are not affected by Methoprene up to 1,000 ppb ⁴⁶.

Preliminary investigations by Cliburn⁴⁷ were reported on the effects of Methoprene on various life stages of different amphibian species (*B. woodhousei*, *R. catesbeiana* and *R. pipiens*). Acute studies on *R. catesbeiana* and *R. pipiens* larvae indicate LC₅₀ values >10,000 ppb and *B. woodhousei* adult LC₅₀ values >1,000 ppb (highest dose tested). Chronic studies on *B. woodhousei* indicate a 22 day LC₅₀ >1,000 ppb and LC₅₀ > 1,000 ppb for *R. catesbeiana* and *R. pipiens*. No other adverse effects were reported.

Rate of release and data generated under laboratory and field conditions with Methoprene mosquito product formulations, including slow release briquet formulations, indicate a maximal rate of release of ≤ 4 ppb. Data on nontarget organism support margins of safety of >200 for nearly all organisms tested. Therefore, exposure to Methoprene will not reach levels which are toxic to aquatic nontarget species either after acute or chronic exposure ^{48,49,50}.

Based upon review of the data submitted to the Agency between 1993 and 1996, EPA concluded in 1996 that the following label changes should be implemented on all solid Methoprene mosquito products:

- Remove the label restriction “do not use in fish-bearing waters” from all briquet and pellet labels and
- Add the label warning “this product is toxic to aquatic dipteran (mosquitoes) and chironomid (midge) larvae” to all briquet and pellet labels.

Additional Data Required

Reregistration of the active ingredient Methoprene and all end-use products was completed in 1997.

Product Labeling Changes Required

All labeling changes with regard to fish and aquatic invertebrates were completed in 1996. No additional label changes are required.

Regulatory Conclusions

- The studies available to EPA indicate that the biochemical insect growth regulator Methoprene is of low toxicity and poses very little hazard to people and other non-target species.
- Ecological concerns contained in the 1991 Methoprene R.E.D. FACTS document related to toxicity to estuarine invertebrates have been alleviated as a result of submission of the estuarine invertebrate life cycle toxicity study in 1996, which indicated minimal chronic risk to Mysid Shrimp.
- All Methoprene end-use products completed the reregistration process in 1997 and all reregistration data requirements and label changes have been completed.

End Notes

Updated (April 2001) Methoprene RED Fact Sheet Literature Cited:

1. Hallesy, Shott & Hill (1972). Effects of a Single Oral Dose of 10g/kg of ZR-515 on Rats. Syntex Research. Report #71-R-72-ZR-515-PO-TX. MRID #'s 00024607, 00088628.
2. Shindler & Brown (1984). Acute Oral Toxicity of S-Methoprene in Rats. Syntex Research. Report # 7182-33. MRID #00150132.
- 3 a.) Hallesy, Shott & Hill (1972). Acute Oral Toxicity of ZR-515 for Dogs. Syntex Research. Report #99-D-72-ZR-515-PO-TX. MRID #00088630.
- 3 b.). Hallesy; Shott & Hill (1972). Effect of a Single Oral Dose of 10g/Kg of ZR-515 on Dogs. Syntex Research. Report # 70-D-72-ZR-515-PO-TX. MRID #'s 00088631, 00024609.
4. Hamilton (1972). Acute Dermal Toxicity Study with ZR-515 Technical in Albino Rabbits. IBT Laboratories. Report #A1547. MRID #00024617.
5. Brown (1984). Acute Dermal Toxicity of S-Methoprene in Rabbits. SRI Laboratories. Report # 7182-35. MRID #00150133.
6. Hiddeman (1972). Acute Inhalation Toxicity of ALTOSID (Technical Grade) in Rats. Hazelton Laboratories. Report #777-102. MRID #00024619.
7. Olson (1972). Acute Inhalation Toxicity in Guinea Pigs. Hazelton Laboratories. Report #777-102. MRID #00024620.
8. Hill (1973). Primary Eye Irritation with Altosid Using Rabbits. Syntex Research. Report #251-B-72-ZR-515-EY-LL. No MRID #.
9. Hill (1973). Primary Dermal Irritation Study of Altosid in Rabbits. Syntex Research. Report #250-B-72-ZR-515-SK-LL. No MRID#.
10. Brown (1984). Primary Eye Irritation of S-Methoprene in Rabbits. SRI Laboratories. Report # 7182-6. MRID #00150134.
11. Schindler & Brown (1984). Primary Skin Irritation of S-Methoprene in Rabbits. SRI Laboratories. Report #7182-34. MRID # 00150135.
12. Nagayoshi. (1975). Skin Sensitization Study of Altosid in Guinea Pigs. Nomura Research Institute. Report No. NRI-PL-74-2466. No MRID #.
13. Jorgenson & Sasmore (1972). Toxicity Studies of Altosid Technical (1) Ninety-Day Subacute Toxicity Study of Altosid Technical in Rats (2) Ninety-Day Subacute Toxicity Study of Altosid Technical in Dogs. SRI Laboratories. Report #LSC 1833. MRID #'s 00024612, 00088633.

14. Nakasawa (1975). Rabbit Subacute Dermal Toxicity of Altosid. Nomura Research Institute. Report # NRI-PL-74-2465. No MRID #.
15. Olsen & Willigan (1972). Three Week Subacute Inhalation Exposure-Rats: Altosid (Technical Grade). Hazelton Laboratories. Report #777-103. MRID #'s 00024621, 00088644.
16. Wazeter & Goldenthal (1975). Altosid Two Year Oral Toxicity in Rats. IRDC Laboratories. Report #322-001. MRID #'s 00010739, 00010599, 00010779, 00130943.
17. Wazeter & Goldenthal (1975). Altosid Eighteen Month Oral Carcinogenic Study in Mice. IRDC Laboratories. Report #322-003. MRID #'s 00010600, 00010740, 00010780.
18. Nakasawa & Matsumiys (1975). Determination of Teratogenic Potential of Altosid Administered Orally to Rabbits. Nomura Research Institute. Report # NRI-PL-74-2485. MRID #'s 00029250, 00029251.
19. Nakasawa, Nomura, Furuhashi, Mihori & Ikeya (1975). Determination of Teratogenic Potential of Altosid Administered Orally to Mice. Nomura Research Institute. No MRID #.
20. Kileen & Rapp (1974). A Three Generation Reproduction Study of Altosid in Rats. Biodynamics. Report # 73R-892. MRID #'s 00010741, 00010781.
21. Hsia; Adarnovics; Kreamer (1979). Microbial Mutagenicity Studies of Insect Growth Regulators and Other Potential Insecticidal Compounds in *Salmonella typhimurium*, Chemosphere, 8, 521-529. MRID #05018270.
22. Johnston (1973). ZR-515 Dominant Lethal Test in Rats. Woodard Research Corp. Report #CDL 223415-D. MRID #'s 00010545, 00084094.
23. Stewart & Riccio. (1984). *In Vitro* Detection of Mitotic Crossing-Over, Gene Conversion and Reverse Mutation with Zoecon Corporation's S-Methoprene. SRI Laboratories. Report # LSC-5854. MRID #'s 00150136, 00150137.
24. Stewart & Riccio. (1984). *In Vitro* Microbiological Mutagenic Assays of Zoecon Corporation's S-Methoprene. SRI Laboratories. Report #LSC-5854. MRID #00150137.
- 25a. Chasseaud, Hawkins, Franklin, *et al.* (1974) The metabolic fate of 5-¹⁴C-Isopropyl, 11-methoxy-3,7,11-trimethyldodeca-2,4-dienoate Altosid in the Rat. Huntingdon Research Center, UK. Report # ZCNI/74174. MRID #'s 00010866, 00065109, 00010378.
- 25b. Quistad, Staiger and Schooley (1974). Cholesterol and Bile Acids via Acetate from the Insect Juvenile Hormone Analog Methoprene, *Life Science* 15, 1797. MRID #'s 00010679, 00010867, 00066329.

26. Rooks. (1972). Report on Mammalian Endocrine Testing Performed on ZR-515. Syntex Research. MRID #'s 00024605, 00088626.
27. Quistad, Staiger & Schooley. (1975). Environmental Degradation of the Insect Growth Regulator Methoprene. II. Photodecomposition. J. Agr. Food Chem. Vol 23 (2):299. MRID #5008610.
28. Schaefer & Dupras. (1973). Insect Development Inhibitors. 4: Persistence of ZR-515 in Water. J. of Economic Entomology. Vol 66(4):923-925. MRID #5008625.
29. Schooley, Creswell, Staiger & Quistad. (1975). Environmental Degradation of the Insect Growth Regulator Methoprene. IV. Soil Metabolism. J. Agr. Food Chem. Vol. 23 (3):369-373. MRID #5008315.
30. Schooley, Bergot, Dunham & Siddall. (1975). Environmental Degradation of the Insect Growth Regulator Methoprene. II. Metabolism by Aquatic Organisms. J. Agr. Food Chem. 23(2):293. MRID # 5008622.
31. Fink, R. (1972). Eight Day Dietary LC50 in Mallard Ducks with ZR-515. Hazleton Laboratories. MRID# 0012754.
32. Fink, R. (1972). Eight Day Dietary LC50 in Bobwhite Quail with ZR-515. Hazleton Laboratories. MRID# 0012755.
33. Fink, R. and F.E. Reno (1973). One-Generation Reproduction Study in Mallard Ducks with ZR-515. Hazleton Laboratories. MRID#0010634.
34. Fink, R. and F.E. Reno (1973). One-Generation Reproduction Study in Bobwhite Quail with ZR-515. Hazleton Laboratories. MRID# 0010635.
35. McAllister, W. et.al. (1985). Acute toxicity of (S)-Methoprene technical to Rainbow Trout (*Salmo gairdneri*) Springborn Bionomics, Inc.. MRID# 43351901.
36. Suprenant, D. (1985). Acute Toxicity of (S)-Methoprene technical to Bluegill Sunfish (*Lepomis macrochirus*). ABC Laboratories. MRID #43351902.
37. Cohle, P. et al. (1993) Early Life Stage Toxicity of (S)-Methoprene technical to Fathead Minnow (*Pimephales promelas*) in a flow-through system. ABC Laboratories. MRID #42811201.
38. Suprenant, D. (1985) Acute toxicity of (S)-Methoprene technical to Daphnids (*Daphnia magna*). Springborn Bionomics. MRID #43163301.
39. LeBlanc, G. (1975) The chronic toxicity of Altosid, TH-6040 and R-20458 to *Daphnia magna*. EG&G Bionomics. MRID #00010856.
40. Machado, M. (1992) (S)-Methoprene technical – Acute toxicity to Mysid shrimp (*Mysidopsis bahia*) under flow-through conditions. Springborn Laboratories. MRID #42837301.

41. Sousa, J. (1996) (S)-Methoprene technical – Chronic toxicity to Mysids (*Mysidopsis bahia*) under flow-through conditions. Springborn Laboratories. MRID# 44022101.
42. Sleight, B.H. (1972) Acute Toxicity of Altosid to the Atlantic Oyster (*Crassostrea virginica*). Bionomics, Inc. MRID #00010851.
43. Sleight, B.H. (1973) Acute Toxicity of Altosid to the Atlantic Oyster (*Crassostrea virginica*). Bionomics, Inc. MRID #00010852.
44. Miura T and Takahashi R. M. (1973) Insect Developmental Inhibitors. 3. Effect on Nontarget Organisms. *Journal of Economic Entomology*. 66(4): 917-922. MRID #05009929.
45. Miura T and Takahashi R. M. (1974) Insect Developmental Inhibitors. Effects of Candidate Mosquito Control Agents on Nontarget Aquatic Organisms. *Environmental Entomology*. 3(4):631-636. MRID#00129970.
46. Hester, P. G., Rathburn, C. B. and Boike, A. H. (1980). Effects of Methoprene on Non-Target Organisms When Applied as a Mosquito Larvicide. Proceedings of the Florida Anit-Mosquito Association. 16-20. No MRID#.
47. Cliburn, J. W. (1973). Completion Report: Effects of Altosid (formerly Z-515) on Selected Non-Target Organisms (Fish and Amphibians) When Used for Control of Aquatic Insects. University of Southern Mississippi, Hattiesburg, MS to The Zoecon Corporation, Palo Alto, CA. MRID #'s 00084096, 00010405
48. Judy, D. and B. Howell (1992) Concentration of Methoprene found in Freshwater Microcosms Treated with Sustained Release Altosid formulations. ABC Laboratories. MRID# 42811202.
49. Ross, D.H., *et. al* (1994). Methoprene Concentrations in Freshwater Microcosms Treated with Sustained-Release Altosid® Formulations. *Jour. American Mosquito Control Association*. 10(2): 202-210. No MRID#.
50. Scientific Peer Review Panel of the Metropolitan Mosquito control district (MMCD). (1996). An Assessment of the Non-Target Effects of the Mosquito Larvicides, Bti and Methoprene in Metropolitan Area Wetlands. Minneapolis Metropolitan Mosquito Control District. MRID#44022102.